Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

Summary

Propanc Biopharma has cleared the path to initiate a Phase 1b clinical study of PRP, described as a breakthrough cancer therapy, in patients with advanced solid tumors. The open-label, dose escalation and expansion study represents the world-first evaluation of this investigational treatment.